Oppenheimer buyers of Avalo Therapeutics ahead of lutikizumab data

Oppenheimer recommends investors to be buyers of Avalo Therapeutics (AVTX) in anticipation of the presentation of lutikizumab’s open-label Phase 2 data in about 40 treatment-naive hidradenitis suppurativa patients late this week. The firm, which forecasts “strong results for luti” at the EADV conference given its substantial benefit previously shown in a difficult-to-treat, TNF-refractory disease population, would expect ‘009 – with its multiple advantages over luti – to show “at least as good as, and potentially better, efficacy” when LOTUS reads out in mid-2026, says the analyst. The firm has an Outperform rating and $35 price target on Avalo shares.